Karuna Therapeutics, Inc. (KRTX) [Rocket]

Overview

Karuna Therapeutics, Inc. (KRTX)

Add to portfolio

1m \| 3m \| 6m \| 1y \| 2y \| 5y \| 10y

Recent News + Filings (All items)

Date Filed	Type	Description
10/10/2023	4	Form 4 - Statement of changes in beneficial ownership of securities:
10/10/2023	144	Form 144 - Report of proposed sale of securities:
10/03/2023	4	Brown Jason Parker (CFO) has filed a Form 4 on Karuna Therapeutics, Inc.
10/03/2023	3	Brown Jason Parker (CFO) has filed a Form 3 on Karuna Therapeutics, Inc.
08/24/2023	4	Ignelzi Troy A. (CFO) has filed a Form 4 on Karuna Therapeutics, Inc.
08/22/2023	144	Form 144 - Report of proposed sale of securities:
08/10/2023	4	Brannan Stephen K. (Chief Medical Officer) has filed a Form 4 on Karuna Therapeutics, Inc.

Revenue Mix by Segment

Financial Summary (All financials)

In millions, except per share items	Dec-31-22	Dec-05-22	Dec-31-21	Dec-05-21	Dec-31-20	Dec-31-19	Dec-31-18	Dec-31-17
Revenues	10.6	224.2	37.0	128.2	0.0	0.0	0.0	0.0
Revenue growth	-71.2%	74.9%
Cost of goods sold	0.0	300.3	0.0	180.8	0.0	0.0	0.0	0.0
Gross profit	10.6	-76.1	37.0	-52.6	0.0	0.0	0.0	0.0
Gross margin	100.0%	-33.9%	100.0%	-41.0%
Selling, general and administrative	300.3		180.8		71.8	45.4
Research and development							11.5	3.6
General and administrative		76.1		52.6			3.0	1.2
EBIT	-260.2	-289.7	-143.7	-143.9	-65.2	-42.5	-14.5	-4.8
EBIT margin	-2445.8%	-129.2%	-388.9%	-112.2%
Pre-tax income	-274.9	-274.9	-143.8	-143.8	-68.5	-44.0	-17.5	-6.0
Income taxes	1.4	1.4	0.0	0.0	0.0	0.0	0.0	0.0
Tax rate						0.0%	0.0%	0.0%
Net income	-276.3	-276.3	-143.8	-143.8	-68.6	-44.0	-17.5	-6.0
Net margin	-2597.9%	-123.2%	-389.0%	-112.2%

Diluted EPS	($8.74)	($8.74)	($4.94)	($4.94)	($2.59)	($3.68)	($4,378,000.00)
Shares outstanding (diluted)	31.6	31.6	29.1	29.1	26.4	12.0	0.0

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.